Phocas Financial Corp. Reduces Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Phocas Financial Corp. decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 85.0% during the 4th quarter, Holdings Channel reports. The firm owned 16,407 shares of the specialty pharmaceutical company’s stock after selling 93,053 shares during the period. Phocas Financial Corp.’s holdings in Supernus Pharmaceuticals were worth $593,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in SUPN. Bank of New York Mellon Corp grew its holdings in Supernus Pharmaceuticals by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock worth $14,449,000 after acquiring an additional 27,134 shares during the last quarter. Quartz Partners LLC boosted its holdings in shares of Supernus Pharmaceuticals by 3.0% during the fourth quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company’s stock worth $1,031,000 after purchasing an additional 820 shares during the period. Handelsbanken Fonder AB grew its stake in shares of Supernus Pharmaceuticals by 11.0% in the fourth quarter. Handelsbanken Fonder AB now owns 19,116 shares of the specialty pharmaceutical company’s stock worth $691,000 after purchasing an additional 1,900 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at approximately $92,000. Finally, Principal Financial Group Inc. raised its position in Supernus Pharmaceuticals by 4.0% during the 4th quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company’s stock valued at $10,730,000 after purchasing an additional 11,321 shares during the last quarter.

Insiders Place Their Bets

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last three months. Company insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $57.00 to $36.00 in a research report on Wednesday, February 19th.

Supernus Pharmaceuticals Trading Up 0.4 %

Shares of SUPN opened at $32.81 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The firm’s 50-day moving average price is $37.34 and its 200-day moving average price is $35.39. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 30.66 and a beta of 0.90.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.